Investigational drug · Phase 2
Relma-cel
Also called: CAR, CD19-targeted Chimeric Antigen Receptor T Cells, B-cell maturation antigen directed chimeric antigen receptor -T cell, BCMA
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
21
Any phase or sponsor naming "Relma-cel"
First trial start
2021
Jan 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Relma-cel", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Non-Hodgkin Lymphoma
- Large B-cell Lymphoma
- Multiple Myeloma
- Mantle Cell Lymphoma
Approved drugs for the same conditions: Multiple myeloma · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Relma-cel" as an intervention, largest first.
- Relmacabtagene Autoleucel in Patients With LBCLStatus unknown
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT06142175 · 200 participants (planned) · Start Dec 28, 2022 · Primary completion Dec 31, 2024
Drug: Relmacabtagene Autoleucel · For: Large B-cell Lymphoma
Sites: Shanghai, China
- Relmacabtagene Autoleucel in Hematologic MalignanciesNot yet recruiting
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT06142188 · 150 participants (planned) · Start Dec 28, 2023 · Primary completion Dec 31, 2038
Drug: Relmacabtagene Autoleucel · For: Lymphoma, B-Cell; Large B-cell Lymphoma; Follicular Lymphoma
Sites: Beijing, China · 2 sites in all
- Chidamide Bridging for CAR-T TherapyPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT05370547 · 120 participants (planned) · Start May 25, 2022 · Primary completion Jun 30, 2024
Drug: Chidamide; Fludarabine and cyclophosphamide and 1 more · For: Non Hodgkin's Lymphoma
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 13 sites in all
- Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLActive, not recruiting
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT06093841 · 46 participants (planned) · Start Nov 3, 2023 · Primary completion Jan 21, 2024
Drug: Relmacabtagene Autoleucel; Fludarabine and 1 more · For: Lymphoma, Large B-Cell, Diffuse; Follicular Lymphoma Grade 3B; High-grade B-cell Lymphoma and 1 more
Sites: Guangzhou, China; Zhengzhou, China; Changsha, China · 13 sites in all
Zhengzhou UniversityAcademic, hospital or other
NCT07198464 · 30 participants (planned) · Start Oct 7, 2025 · Primary completion Oct 1, 2029
Drug: Relmacabtagene autoleucel and transplantation · For: Primary Central Nervous System Lymphoma (PCNSL)
- Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07077512 · 30 participants (planned) · Start Sep 15, 2025 · Primary completion Jan 15, 2027
Drug: Autoleucel (Relmacabtagene Autoleucel); Sintilimab (PD-1 inhibitor) · For: Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL); Follicular Lymphoma ( FL)
Sites: Guangzhou, China · 3 sites in all
Ruijin HospitalAcademic, hospital or other
NCT06876688 · 30 participants (planned) · Start Nov 30, 2023 · Primary completion Nov 30, 2028
Drug: Relma-cel Followed by Tislelizumab · For: CNS Lymphoma
Sites: Beijing, China; Guangzhou, China; Henan, China · 6 sites in all
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T TherapiesActive, not recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT06220097 · 28 participants (planned) · Start Feb 1, 2022 · Primary completion Aug 1, 2024
Drug: Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells · For: B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma Refractory
Sites: Wuhan, China
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT05765006 · 24 participants (planned) · Start Feb 24, 2023 · Primary completion Dec 30, 2024
Drug: Relma-cel · For: Systemic Lupus Erythematosus
Sites: Shanghai, China
- Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruiting
Ruijin HospitalAcademic, hospital or other
NCT07326371 · 24 participants (planned) · Start Mar 2026 · Primary completion Jul 2027
Drug: Glofitamab; Obinutuzumab and 2 more · For: DLBCL - Diffuse Large B Cell Lymphoma
Newest research
PubMed records naming it or its code names, newest first.
- Genetically engineered extracellular vesicles with chimeric antigen receptors of human stem cell-derived neutrophils targeting fibroblast activation protein to modulate tumor microenvironment.
Esmonde C, Sun L, Jin G, et al. · Bioact Mater 2027
- Geometry-optimized passive SPME sampler for time-weighted average determination of volatile organic compounds in air: Proof of concept.
Ibragimova OP, Omarova A, Sovetova D, et al. · Talanta 2027
- Panaxytriol up-regulates CYP2B6 expression through PXR and CAR and their interactions with RXRα and SRC-1.
Huang L, Du X, Gu Q, et al. · J Ethnopharmacol 2027
- In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions.
Zhao Y, Liu Y, Peng X, et al. · Genes Dis 2027
- Synergistic antibacterial effects of zinc oxide with cinnamaldehyde or carvacrol against Brochothrix thermosphacta and their application in chicken breast preservation.
Li D, Chen F, Jia F, et al. · Int J Food Microbiol 2027
- Perfluoroalkylated polymeric constructs bypass endosomal entrapment to stimulate transnuclear delivery in proliferating and non-proliferating cells.
Wang Y, Li F, Xie H, et al. · J Colloid Interface Sci 2027
Also in development for Non-Hodgkin Lymphoma
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- XNW5004EZH2iPhase 37 trials
Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- Rondecabtagene autoleucelLYL314Phase 32 trials
Lyell Immunopharma, Inc. · Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- GNC-038Phase 24 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- AZD3470Phase 22 trials
AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- CYT-0851Phase 21 trial
Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.